Amneal Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 4/4
Amneal Pharmaceuticals CEO'su Chirag Patel, Jan2005 tarihinde atandı, in görev süresi 19.83 yıldır. in toplam yıllık tazminatı $ 2.37M olup, şirket hissesi ve opsiyonları dahil olmak üzere 31.6% maaş ve 68.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 7.04% ine doğrudan sahiptir ve bu hisseler $ 196.23M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.3 yıl ve 6.5 yıldır.
Anahtar bilgiler
Chirag Patel
İcra Kurulu Başkanı
US$2.4m
Toplam tazminat
| CEO maaş yüzdesi | 31.6% |
| CEO görev süresi | 19.8yrs |
| CEO sahipliği | 7.0% |
| Yönetim ortalama görev süresi | 5.3yrs |
| Yönetim Kurulu ortalama görev süresi | 6.5yrs |
Son yönetim güncellemeleri
Recent updates
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price
Nov 10
Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success
Jul 10Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price
Apr 15Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?
Mar 19Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry
Dec 28Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company
Dec 10Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?
Nov 28Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt
Sep 24Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?
Aug 08Amneal Pharmaceuticals Could Have An Upbeat Q2
Jul 10These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively
Apr 18Amneal Pharmaceuticals: Risk Still Persists
Jan 23Amneal Pharma reaffirms 2022 guidance
Jan 10Amneal joins hands with Orion to commercialize generic products in Europe and more countries
Jan 04Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load
Dec 20Amneal Pharmaceuticals large shareholder TPG cuts stake
Dec 14FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203
Nov 11Amneal Pharmaceuticals Q3 2022 Earnings Preview
Nov 03Amneal Pharmaceuticals: A Small 'Thumbs Up'
Oct 28Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet
Sep 01Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment
Aug 31Amneal Pharmaceuticals Q2 2022 Earnings Preview
Aug 04CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$184m |
| Jun 30 2024 | n/a | n/a | -US$175m |
| Mar 31 2024 | n/a | n/a | -US$169m |
| Dec 31 2023 | US$2m | US$750k | -US$84m |
| Sep 30 2023 | n/a | n/a | US$10m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | n/a | n/a | -US$135m |
| Dec 31 2022 | US$5m | US$750k | -US$130m |
| Sep 30 2022 | n/a | n/a | -US$132m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | US$2m |
| Dec 31 2021 | US$5m | US$724k | US$11m |
| Sep 30 2021 | n/a | n/a | US$14m |
| Jun 30 2021 | n/a | n/a | US$9m |
| Mar 31 2021 | n/a | n/a | -US$17m |
| Dec 31 2020 | US$2m | US$1 | US$91m |
| Sep 30 2020 | n/a | n/a | US$62m |
| Jun 30 2020 | n/a | n/a | -US$194m |
| Mar 31 2020 | n/a | n/a | -US$199m |
| Dec 31 2019 | US$446k | US$44k | -US$362m |
| Sep 30 2019 | n/a | n/a | -US$339m |
| Jun 30 2019 | n/a | n/a | -US$67m |
| Mar 31 2019 | n/a | n/a | -US$69m |
| Dec 31 2018 | US$325k | n/a | -US$21m |
Tazminat ve Piyasa: Chirag 'nin toplam tazminatı ($USD 2.37M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 6.55M ).
Tazminat ve Kazançlar: Chirag 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Chirag Patel (57 yo)
19.8yrs
Görev süresi
US$2,370,385
Tazminat
Mr. Chirag K. Patel has been Co-Chief Executive Officer, President and Director of Amneal Pharmaceuticals, Inc. since August 3, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as D...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 19.8yrs | US$2.37m | 7.04% $ 196.2m | |
| Co-Founder | 22.8yrs | US$2.37m | 8.16% $ 227.6m | |
| Executive VP & CFO | 4.7yrs | US$1.89m | 0.17% $ 4.8m | |
| Senior VP | 2.8yrs | US$1.35m | 0.019% $ 516.4k | |
| Executive VP & Chief Human Resources Officer | 10.8yrs | US$1.53m | 0.094% $ 2.6m | |
| Executive VP & Chief Commercial Officer of Generics | 6.8yrs | US$1.94m | 0.083% $ 2.3m | |
| Head of Investor Relations | no data | Veri yok | Veri yok | |
| Senior Vice President of Corporate Development | 1.8yrs | Veri yok | Veri yok | |
| Senior VP of Strategic Sourcing & Supply Management | 1.8yrs | Veri yok | Veri yok | |
| Chief Quality Officer | 5.8yrs | Veri yok | Veri yok | |
| Senior VP & Chief Scientific Officer of Generics | 4.8yrs | Veri yok | Veri yok | |
| Vice President & Head of Medical Affairs | no data | Veri yok | Veri yok |
5.3yrs
Ortalama Görev Süresi
54.5yo
Ortalama Yaş
Deneyimli Yönetim: AMRX 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 19.8yrs | US$2.37m | 7.04% $ 196.2m | |
| Co-Founder | 22.8yrs | US$2.37m | 8.16% $ 227.6m | |
| Independent Chairman of the Board | 5.3yrs | US$299.08k | 0.24% $ 6.6m | |
| Independent Director | 6.5yrs | US$302.20k | 0.085% $ 2.4m | |
| Independent Director | 6.5yrs | US$244.70k | 0.097% $ 2.7m | |
| Independent Director | 4.9yrs | US$254.70k | 0.079% $ 2.2m | |
| Independent Director | 4.9yrs | US$277.20k | 0.087% $ 2.4m | |
| Director | 6.5yrs | US$217.20k | 0.66% $ 18.5m | |
| Independent Director | 2.3yrs | US$267.04k | 0.030% $ 841.3k | |
| Independent Director | 6.5yrs | US$217.20k | 0.081% $ 2.3m | |
| Independent Director | 4.9yrs | US$284.70k | 0.083% $ 2.3m |
6.5yrs
Ortalama Görev Süresi
57yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: AMRX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.5 yıldır).